Diabetes Care
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Diabetes Care 29:1915-1917, 2006
DOI: 10.2337/dc06-0877
© 2006 by the American Diabetes Association
This Article
Right arrow Extract Freely available
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lo, J. C.
Right arrow Articles by Ferrara, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lo, J. C.
Right arrow Articles by Ferrara, A.
Social Bookmarking
Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Clinical Care/Education/Nutrition
Brief Report

Increased Prevalence of Gestational Diabetes Mellitus Among Women With Diagnosed Polycystic Ovary Syndrome

A population-based study

Joan C. Lo, MD1,2, Seth L. Feigenbaum, MPH, MD3,4, Gabriel J. Escobar, MD1,5, Jingrong Yang, MA1, Yvonne M. Crites, MD6 and Assiamira Ferrara, MD, PHD1,7

1 Division of Research, Kaiser Permanente of Northern California, Oakland, California
2 Division of Endocrinology, Department of Medicine, University of California at San Francisco, San Francisco, California
3 Division of Reproductive Endocrinology and Infertility, Kaiser Permanente Medical Center, San Francisco, California
4 Department of Obstetrics, Gynecology and Reproductive Sciences, University of California at San Francisco, San Francisco, California
5 Department of Inpatient Pediatrics, Kaiser Permanente Medical Center, Walnut Creek, California
6 Division of Perinatology, Department of Obstetrics and Gynecology, Kaiser Permanente Medical Center, Santa Clara, California
7 Department of Epidemiology, School of Public Health and Community Medicine, University of Washington, Seattle, Washington

Address correspondence and reprint requests to Joan C. Lo, MD, Division of Research, Kaiser Permanente of Northern California, 2000 Broadway St., 2nd Floor, Oakland, CA 94612-2304. E-mail: joan.c.lo{at}kp.org

Abbreviations: GDM, gestational diabetes mellitus • KPNC, Kaiser Permanente of Northern California • PCOS, polycystic ovary syndrome


   INTRODUCTION
TOP
 INTRODUCTION
RESEARCH DESIGN AND METHODS
 RESULTS
 CONCLUSIONS
 References
 
Gestational diabetes mellitus (GDM), defined as carbohydrate intolerance at onset of pregnancy (or first recognition), affects ~4–7% of pregnancies overall (1–6). Common risk factors include nonwhite race/ethnicity, older age, obesity, and prior GDM (3–7). Other conditions predisposing to glucose intolerance might also increase the risk of GDM.

Polycystic ovary syndrome (PCOS) is a reproductive condition characterized by chronic anovulation, insulin resistance, and androgen excess (8–10). Affected women have an increased risk of glucose intolerance and type 2 diabetes (11–14). Some, but not all, studies suggest the risk of GDM is higher among PCOS versus non-PCOS women (15–18), and several studies note an increased prevalence of polycystic ovarian morphology and symptoms in women with prior GDM (19–21). This study examines the prevalence and association of PCOS and GDM among a large multiethnic population of pregnant women in northern California.


   RESEARCH DESIGN AND METHODS
TOP
 INTRODUCTION
 RESEARCH DESIGN AND METHODS
RESULTS
 CONCLUSIONS
 References
 
Kaiser Permanente of Northern California (KPNC) is a large integrated health care delivery system providing comprehensive medical care for >3,000,000 members in northern California. There are 14 delivery hospitals with >30,000 births/year. Comprehensive health plan databases of all hospitalizations, ambulatory visits, and laboratory tests are available and linked by unique patient identifiers (22). This study was approved by the KPNC Institutional Review Board.

As previously described (1), we used hospitalization databases to identify third trimester pregnancies between 1 January 2002 and 31 December 2004 among women aged 16–44 years, ascertaining the earliest pregnancy for each woman in this period. Maternal age, race/ethnicity, and single versus multiple gestation status were obtained from hospitalization databases. Approximately 95% of pregnancies within KPNC are screened for GDM (1). In accordance with national guidelines, if the random 50-g 1-h oral glucose tolerance test is abnormal, a diagnostic 100-g 3-h oral glucose tolerance test is performed following a 12-h fast (3,23). The KPNC GDM registry data (1) were used to ascertain GDM according to the Carpenter-Coustan criteria (two or more plasma glucose levels achieving the following: fasting ≥5.3 mmol/l, 1 h ≥10 mmol/l, 2 h ≥8.6 mmol/l, and 3 h ≥7.8 mmol/l) (3,23,24). Women with preexisting diabetes were excluded, as previously described (1).

We searched outpatient databases to identify women who received at least one outpatient diagnosis of PCOS (ICD-9 code 256.4) between 1 January 1994 and 31 December 2004 before their delivery date, in the absence of confounding conditions (e.g., congenital adrenal hyperplasia, Cushing’s syndrome, ovarian tumor, or prolactinoma) (25). To support the PCOS diagnosis, we identified whether women had any additional PCOS-related diagnoses (androgen excess, oligo/amenorrhea, anovulation, infertility, menstrual irregularity, insulin resistance, and acanthosis nigricans). Because of potential PCOS under ascertainment, we separately identified women without diagnosed PCOS who had any diagnosis of a PCOS symptom ("PCOS symptom only"), including oligo/amenorrhea, ovulatory dysfunction, hirsutism, and/or hyperandrogenism in the 4 years before delivery.

The clinical characteristics and proportion of GDM cases among women by PCOS status were compared using the {chi}2 test and Student’s t test. Multivariable logistic regression was used to examine the association of PCOS, symptoms, and GDM. All analyses were conducted using SAS version 9.0 (Cary, NC).


   RESULTS
TOP
 INTRODUCTION
 RESEARCH DESIGN AND METHODS
 RESULTS
CONCLUSIONS
 References
 
Between 2002 and 2004, 92,933 pregnant women screened for GDM were identified. We excluded 4,335 (4.5%) women without GDM screening. The racial/ethnic distribution was 39.2% white, 6.5% black, 24.4% Hispanic, and 18.7% Asian. A total of 5,725 (6.2%) women met GDM criteria.

There were 1,542 (1.7%) women with diagnosed PCOS, of whom 97% had other PCOS-supporting diagnoses. An additional 6,509 (7.0%) women without diagnosed PCOS had diagnoses of oligo/amenorrhea, ovulatory dysfunction, hirsutism, and/or hyperandrogenism. Women with PCOS were slightly older, more likely to be white, and have multiple gestation compared with women with no PCOS or symptoms (Table 1). The prevalence of GDM was highest among women with PCOS and intermediate among those with PCOS symptoms only.


View this table:
[in this window]
[in a new window]
  		Table 1— Demographic and clinical characteristics of identified pregnancies, 2002–2004

 
Multivariable logistic regression was used to investigate the association of PCOS and GDM, adjusting for maternal age, race/ethnicity, and multiple (versus single) gestation status. We found that women with PCOS had a more than twofold increased odds of GDM (adjusted odds ratio [OR] 2.44 [95% CI 2.10–2.83]), while women with PCOS symptoms only had an intermediate increased odds (1.40 [1.27–1.54]) compared with women with no PCOS or symptoms. Higher maternal age (1.10 [1.10–1.11]), multiple gestation (1.29 [1.07–1.55]), Hispanic ethnicity (1.81 [1.68–1.94]), and Asian race (2.25 [2.09–2.41]) were also associated with an increased odds of GDM in adjusted analyses.


   CONCLUSIONS
TOP
 INTRODUCTION
 RESEARCH DESIGN AND METHODS
 RESULTS
 CONCLUSIONS
References
 
Among a large population of pregnant women receiving health care within northern California, women with diagnosed PCOS had a 2.4-fold increased odds of GDM, independent of age, race/ethnicity, and multiple gestation. These data are consistent with the known association of PCOS and glucose intolerance among nonpregnant women (11–13) and support previous studies suggesting higher rates of GDM among women with PCOS (16,18,26,27). The intermediate increased odds of GDM among women with PCOS symptoms only is consistent with the overlap of metabolic perturbation and reproductive abnormalities and the possibility that some women actually had PCOS. Importantly, this study comprises the first population-based evaluation of the prevalence of GDM among women with PCOS, the strengths of which include the large sample size and identification of the outcome using objective laboratory diagnostic criteria.

Although we demonstrate a clear association between PCOS and GDM, the extent to which obesity contributes to these findings remains key, given the high prevalence of obesity among women with PCOS (25). There is also concern regarding PCOS under ascertainment, potential variability in PCOS diagnosis, and the possibility that some PCOS women did not manifest both androgen excess and anovulation. However, more accurate assessment of PCOS status would likely have magnified our results. Finally, these data pertain only to women achieving advanced gestation since pregnant PCOS women with early miscarriage were not captured.

In conclusion, we found that pregnant women with diagnosed PCOS have a more than twofold increased odds of GDM compared with women without PCOS or symptoms. Further research is needed to clarify the role of obesity in mediating this association, as well as the role of infertility treatment, glucoregulatory drugs, and other factors during preconception care that may impact GDM risk. Studies are also needed to determine whether PCOS women might benefit from management to reduce GDM risk and whether such measures affect pregnancy outcome.


   Acknowledgments
 
This work was supported by the National Institutes of Health (National Institute of Child Health and Human Development, Office of Research on Women’s Health, and National Institute of Diabetes and Digestive and Kidney Diseases: 9 K12 HD052163-0 and R01 DK054834) and the Kaiser Permanente Research Program on Genes, Environment and Health funded by the Wayne and Gladys Valley Foundation, the Ellison Medical Foundation, and Kaiser Foundation Hospitals Health Plan.

The authors thank Isaac Ergas, MPH, Bix Swain, MS, and John Greene, MA, for their helpful technical assistance.


   Footnotes
 
A table elsewhere in this issue shows conventional and Système International (SI) units and conversion factors for many substances.

Received for publication April 26, 2006. Accepted for publication April 28, 2006.


   References
TOP
 INTRODUCTION
 RESEARCH DESIGN AND METHODS
 RESULTS
 CONCLUSIONS
 References
 

  1. Ferrara A, Kahn HS, Quesenberry CP, Riley C, Hedderson MM: An increase in the incidence of gestational diabetes mellitus: Northern California, 1991–2000. Obstet Gynecol 103:526–533, 2004[Medline]
  2. Dabelea D, Snell-Bergeon JK, Hartsfield CL, Bischoff KJ, Hamman RF, McDuffie RS: Increasing prevalence of gestational diabetes mellitus (GDM) over time and by birth cohort: Kaiser Permanente of Colorado GDM Screening Program. Diabetes Care 28:579–584, 2005[Abstract/Free Full Text]
  3. American Diabetes Association: Gestational diabetes mellitus (Position Statement). Diabetes Care 23 (Suppl. 1):S77–S79, 2000
  4. Dooley SL, Metzger BE, Cho NH: Gestational diabetes mellitus: influence of race on disease prevalence and perinatal outcome in a U.S. population. Diabetes 40 (Suppl. 2):S25–S29, 1991
  5. King H: Epidemiology of glucose intolerance and gestational diabetes in women of childbearing age. Diabetes Care 21 (Suppl. 2):B9–B13, 1998
  6. Kjos SL, Buchanan TA: Gestational diabetes mellitus. N Engl J Med 341:1749–1756, 1999[Free Full Text]
  7. Solomon CG, Willett WC, Carey VJ, Rich-Edwards J, Hunter DJ, Colditz GA, Stampfer MJ, Speizer FE, Spiegelman D, Manson JE: A prospective study of pregravid determinants of gestational diabetes mellitus. JAMA 278:1078–1083, 1997[Abstract]
  8. Dunaif A: Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev 18:774–800, 1997[Abstract/Free Full Text]
  9. Ehrmann DA: Polycystic ovary syndrome. N Engl J Med 352:1223–1236, 2005[Free Full Text]
  10. Franks S: Polycystic ovary syndrome. N Engl J Med 333:853–861, 1995[Free Full Text]
  11. Legro RS, Gnatuk CL, Kunselman AR, Dunaif A: Changes in glucose tolerance over time in women with polycystic ovary syndrome: a controlled study. J Clin Endocrinol Metab 90:3236–3242, 2005[Abstract/Free Full Text]
  12. Legro RS, Kunselman AR, Dodson WC, Dunaif A: Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J Clin Endocrinol Metab 84:165–169, 1999[Abstract/Free Full Text]
  13. Palmert MR, Gordon CM, Kartashov AI, Legro RS, Emans SJ, Dunaif A: Screening for abnormal glucose tolerance in adolescents with polycystic ovary syndrome. J Clin Endocrinol Metab 87:1017–1023, 2002[Abstract/Free Full Text]
  14. Solomon CG, Hu FB, Dunaif A, Rich-Edwards J, Willett WC, Hunter DJ, Colditz GA, Speizer FE, Manson JE: Long or highly irregular menstrual cycles as a marker for risk of type 2 diabetes mellitus. JAMA 286:2421–2426, 2001[Abstract/Free Full Text]
  15. Haakova L, Cibula D, Rezabek K, Hill M, Fanta M, Zivny J: Pregnancy outcome in women with PCOS and in controls matched by age and weight. Hum Reprod 18:1438–1441, 2003[Abstract/Free Full Text]
  16. Mikola M, Hiilesmaa V, Halttunen M, Suhonen L, Tiitinen A: Obstetric outcome in women with polycystic ovarian syndrome. Hum Reprod 16:226–229, 2001[Abstract/Free Full Text]
  17. Turhan NO, Seckin NC, Aybar F, Inegol I: Assessment of glucose tolerance and pregnancy outcome of polycystic ovary patients. Int J Gynaecol Obstet 81:163–168, 2003[Medline]
  18. Urman B, Sarac E, Dogan L, Gurgan T: Pregnancy in infertile PCOD patients: complications and outcome. J Reprod Med 42:501–505, 1997[Medline]
  19. Koivunen RM, Juutinen J, Vauhkonen I, Morin-Papunen LC, Ruokonen A, Tapanainen JS: Metabolic and steroidogenic alterations related to increased frequency of polycystic ovaries in women with a history of gestational diabetes. J Clin Endocrinol Metab 86:2591–2599, 2001[Abstract/Free Full Text]
  20. Kousta E, Cela E, Lawrence N, Penny A, Millauer B, White D, Wilson H, Robinson S, Johnston D, McCarthy M, Franks S: The prevalence of polycystic ovaries in women with a history of gestational diabetes. Clin Endocrinol (Oxf) 53:501–507, 2000[Medline]
  21. Holte J, Gennarelli G, Wide L, Lithell H, Berne C: High prevalence of polycystic ovaries and associated clinical, endocrine, and metabolic features in women with previous gestational diabetes mellitus. J Clin Endocrinol Metab 83:1143–1150, 1998[Abstract/Free Full Text]
  22. Selby JV: Linking automated databases for research in managed care settings. Ann Intern Med 127:719–724, 1997[Medline]
  23. American College of Obstetricians and Gynecologists Committee on Practice Bulletins, Obstetrics: ACOG Practice Bulletin: clinical management guidelines for obstetrician-gynecologists: number 30, September 2001 (replaces Technical Bulletin Number 200, December 1994): gestational diabetes. Obstet Gynecol 98:525–538, 2001[Medline]
  24. Carpenter MW, Coustan DR: Criteria for screening tests for gestational diabetes. Am J Obstet Gynecol 144:768–773, 1982[Medline]
  25. Lo JC, Feigenbaum SL, Yang J, Pressman AR, Selby JV, Go AS: Epidemiology and adverse cardiovascular risk profile of diagnosed polycystic ovary syndrome. J Clin Endocrinol Metab 91:1357–1363, 2006[Abstract/Free Full Text]
  26. Glueck CJ, Wang P, Kobayashi S, Phillips H, Sieve-Smith L: Metformin therapy throughout pregnancy reduces the development of gestational diabetes in women with polycystic ovary syndrome. Fertil Steril 77:520–525, 2002[Medline]
  27. Radon PA, McMahon MJ, Meyer WR: Impaired glucose tolerance in pregnant women with polycystic ovary syndrome. Obstet Gynecol 94:194–197, 1999[Abstract/Free Full Text]

Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 J. Clin. Endocrinol. Metab.Home page
K. E. S. Salley, E. P. Wickham, K. I. Cheang, P. A. Essah, N. W. Karjane, and J. E. Nestler
POSITION STATEMENT: Glucose Intolerance in Polycystic Ovary Syndrome A Position Statement of the Androgen Excess Society
J. Clin. Endocrinol. Metab., December 1, 2007; 92(12): 4546 - 4556.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
M. Luque-Ramirez, F. Alvarez-Blasco, J. I. Botella-Carretero, E. Martinez-Bermejo, M. A. Lasuncion, and H. F. Escobar-Morreale
Comparison of Ethinyl-Estradiol Plus Cyproterone Acetate Versus Metformin Effects on Classic Metabolic Cardiovascular Risk Factors in Women with the Polycystic Ovary Syndrome
J. Clin. Endocrinol. Metab., July 1, 2007; 92(7): 2453 - 2461.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
M. M. Hedderson, A. Ferrara, M. A. Williams, V. L. Holt, and N. S. Weiss
Androgenicity of Progestins in Hormonal Contraceptives and the Risk of Gestational Diabetes Mellitus
Diabetes Care, May 1, 2007; 30(5): 1062 - 1068.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes Spectr.Home page
H. C. Zisser
Polycystic Ovary Syndrome and Pregnancy: Is Metformin the Magic Bullet?
Diabetes Spectr, April 1, 2007; 20(2): 85 - 89.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Extract Freely available
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lo, J. C.
Right arrow Articles by Ferrara, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lo, J. C.
Right arrow Articles by Ferrara, A.
Social Bookmarking
Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum